3-氨基-5-硝基苯甲酰胺 | 75633-69-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-5-硝基苯甲酰胺
• 英文名称: 3-amino-5-nitrobenzamide
• CAS: 75633-69-1
• 化学式: C₇H₇N₃O₃
• 分子量: 181.151
• InChiKey: CPRGSOYWINBLDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氨基-5-硝基苯甲酰胺 在 palladium on activated charcoal 吡啶 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-Amino-5-phenylacetylamino-benzamide
  参考文献：
  名称：

  Nonpeptide Inhibitors of Measles Virus Entry

  摘要：

  Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500 000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head-neck region. The resulting model permitted the identification of two nonpeptidic entry inhibitors. Here, we present the design, synthesis, and bioevaluation of several series of fusion inhibitors and describe their structure-activity relationships (SAR). Five simply substituted anilides show low-mu M blockade of the MV, one of which (AS-48) exhibits IC50 0.6-3.0 mu M across a panel of wild-type MV strains found in the field. Molecular field topology analysis (MFTA), a 2D QSAR approach based on local molecular properties (atomic charges, hydrogen-bonding capacity and local lipophilicity), applied to the anilide series suggests structural modifications to improve potency.

  DOI：

  10.1021/jm0602559
• 作为产物：
  描述：

  3,5-二硝基苯甲酰胺 在 2-氨基-3H-喹唑啉-4-酮 、 potassium carbonate 、 一水合肼 作用下， 以 水 为溶剂， 反应 3.0h， 以48%的产率得到3-氨基-5-硝基苯甲酰胺
  参考文献：
  名称：

  Unravelling 2-aminoquinazolin-4(3H)-one as an organocatalyst for the chemoselective reduction of nitroarenes

  摘要：

  一种新颖的、绿色的、无过渡金属的硝基芳烃还原方法已被探索。首次研究了2-氨基喹唑啉-4(3H)-酮及其衍生物作为氢键有机催化剂，用于活化肼水合物以还原硝基芳烃。

  DOI：

  10.1039/c7nj03333h

文献信息

• PYRIMIDINE DERIVATIVES
  申请人：Kettle Jason Grant

  公开号：US20110046108A1

  公开（公告）日：2011-02-24

  The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
• Inhibitors of the tyrosine kinase EphB4. Part 2: Structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines
  作者：Catherine Bardelle、Tanya Coleman、Darren Cross、Sara Davenport、Jason G. Kettle、Eun Jung Ko、Andrew G. Leach、Andrew Mortlock、Jon Read、Nicola J. Roberts、Peter Robins、Emma J. Williams

  DOI：10.1016/j.bmcl.2008.09.087

  日期：2008.11

  Crystallographic studies of a range of 3-substituted anilinopyrimidine inhibitors of EphB4 have highlighted two alternative C-2 aniline conformations and this discovery has been exploited in the design of a highly potent series of 3,5-disubstituted anilinopyrimidines. The observed range of cellular activities has been rationalised on the basis of physicochemical and structural characteristics.
• Monoazoverbindungen enthaltend mindestens eine Carbonamidgruppe
  申请人：CIBA-GEIGY AG

  公开号：EP0162806B1

  公开（公告）日：1989-01-25
• US4737581A
  申请人：——

  公开号：US4737581A

  公开（公告）日：1988-04-12
• [EN] PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRIMIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2007085833A2

  公开（公告）日：2007-08-02

  [EN] The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R¹, ring A, n, R³, and R⁴ are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.
  [FR] La présente invention concerne des composés de benzamide de Formule (I) ou un sel dérivé pharmaceutiquement acceptable, où R¹, le cycle A, n, R³, et R⁴ sont tels qu'énoncés dans la description. La présente invention a aussi trait à des processus de préparation de tels composés, à des compositions pharmaceutiques les contenant et à leur utilisation dans la fabrication d'un médicament à utiliser comme agent antiproliférateur pour la prévention ou le traitement de tumeurs ou d'autres conditions prolifératrices qui sont sensibles à l'inhibition des kinases EphB4, et/ou EphA2 et/ou Src.